BAMI Platelet Sub-study
Research type
Research Study
Full title
BAMI Platelet Sub-study. Substudy 1 to the BAMI randomised Phase III trial: The effect of intracoronary reinfusion of bone marrow derived mononuclear cells (BM-MNCs) on all-cause mortality in acute myocardial infarction.
IRAS ID
142188
Contact name
Anthony Mathur
Contact email
Sponsor organisation
Queen Mary University of London
Research summary
In the BAMI Platelet Sub-study we plan to investigate the genetic causes of heart attacks.
Platelets are the most important cells involved in the blood clot that causes a heart attack. The cells that make platelets are called megakaryocytes and come from the bone marrow. There is now evidence to suggest that individuals who develop heart attacks may have more aggressive megakaryocytes and platelets than individuals who do not. Recent breakthroughs in genetic research now make it possible to decipher the genetic code in these cells that are important in causing heart attacks.
The hope is by doing this type of genetic research we may be able to understand which genes put people at higher risk of developing heart attacks and therefore be able to develop new treatments which may help to treat patients with heart attacks or in fact prevent them occurring in the first place.
We therefore propose to take a small blood and bone marrow sample from heart attack patients who are taking part in the BAMI trial at Barts Health NHS Trust as these patients will already be having blood and bone marrow taken as part of the BAMI trial.
All of the patients recruited onto the BAMI trial and randomised to the treatment arm would be eligible to take part in the BAMI Platelet Sub-study. The samples taken for testing as part of the BAMI Platelet Sub-study will be anonymous and after collection of samples, participants will be followed up as per the main BAMI trial and there will be no specific follow-up pertaining specifically to the BAMI Platelet Sub-study. v
REC name
London - City & East Research Ethics Committee
REC reference
13/LO/1760
Date of REC Opinion
3 Mar 2014
REC opinion
Further Information Favourable Opinion